Anna Kobilka

Anna Kobilka

Auto-generated profile, based on publicly available information

Anna Kobilka

University of Minnesota 3 Masonic Cancer Center Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points. Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extre mes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression. Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer. See related commentary by Chauhan et al., p. 2323

15 June 2026
Verified
Other
Open access
PDF file
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Supplementary Figure 6. Comparable cfDNA and ctDNA profiles at progression between ENZ and ENZ + AAP arms

15 June 2026
Verified
Other
Open access
PDF file
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Supplementary Figure 4. Copy number changes in the AR gene body and AR enhancer in ctDNA occur independently of changes in ctDNA aneuploidy fraction.

15 June 2026
Verified
Other
Open access
PDF file
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Supplementary Figure 1. Interval between baseline and progression sample collection and time to rPFS.

15 June 2026
Verified
Other
Open access
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Supplementary Data 1. Matched baseline and progression samples

15 June 2026
Verified
Other
Open access
JLJosé C. Valentín López
José C. Valentín López
CYChenxi Yu
Chenxi Yu
TKTodd Knutson
Todd Knutson
AKAnna Kobilka
Anna Kobilka
JLJacqueline Lyman
Jacqueline Lyman
Scott DehmScott Dehm
Scott Dehm
Supplementary Data 5. DNA-seq coverage and log2 copy number ratios of targeted genes relative to control regions